title: Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism.
abstract: OBJECTIVE
  Currently, there is considerable debate as to which method is more accurate for measuring the activity of CYP3A in vivo: cortisol 6beta-hydroxylation clearance (Cl(m(6beta))) or the urinary ratio of 6beta-OHF to F (6beta-OHF/F). Furthermore, the value of measuring endogenous levels of cortisol over a 24 h period (AUC(F)) needs to be confirmed. The aim of the present study was to determine which method was most effective at measuring changes in the in vivo activity of CYP3A: AUC(F), Cl(m(6beta)), or 6beta-OHF/F.
  
  
  METHODS
  A two phase, cross-over design was adopted in this study. A total of 24 subjects (12 males and 12 females) were randomly assigned to one of two groups: the test group subjects were given 250 mg clarithromycin tablets twice a day for a period of 4 d, whereas the control group received a placebo twice daily for a similar period. On d 5 of the study, the last dose of either clarithromycin or placebo was supplemented with an oral dose of 7.5 mg midazolam (MDZ); blood and urine samples were then collected at various times. All samples collected at the same sampling times on d 4 were used to evaluate the effects of MDZ administration on cortisol levels and metabolism. The ratio of 1-hydroxymidazolam (1-OHMDZ) concentration to MDZ concentration at 1 h (MR) was taken as a measure of the in vivo CYP3A activity. AUC(F), Cl(m(6beta)), and 6beta-OHF/F were also used as biomarkers for CYP3A activity.
  
  
  RESULTS
  No correlations were found (either before or after inhibition) between CYP3A activity and any of the following measures: AUC(F), Cl(m(6beta)), or 6beta-OHF/F (r<0.4, P>0.05). After 4 d of clarithromycin administration, CYP3A activity (MR) decreased by 75% (P=0.000), whereas AUC(F) increased by 19% (P=0.040), and Cl(m(6beta)) and 6beta-OHF/F decreased by 54.2% (P=0.000) and 50% (P=0.003), respectively. No significant changes in AUC(F) (P=0.178), or in the amount of urinary 6beta-OHF (P=0.169), or in F (P=0.391) were found over a 24 h time period, either with or without MDZ administration.
  
  
  CONCLUSIONS
  Although Cl(m(6beta)) and 6beta-OHF/F can reflect the decline in CYP3A activity, the impression they provide is neither accurate nor complete. AUC(F) is completely ineffective for evaluating variations in CYP3A activity. MDZ administration had no evident effects on either cortisol metabolism or excretion over a period of 24 h.
authors.affiliation: Research Institute of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences, Central South University, Changsha 410013, China.
authors.forename: Xi
authors.initials: X
authors.lastname: Luo
authors.forename: Xiao-min
authors.initials: XM
authors.lastname: Li
authors.forename: Zhe-yi
authors.initials: ZY
authors.lastname: Hu
authors.forename: Ze-neng
authors.initials: ZN
authors.lastname: Cheng
mesh_terms: D017291:Clarithromycin / Q000494:pharmacology; D018592:Cross-Over Studies; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000031:analogs & derivatives / Q000097:blood / Q000493:pharmacokinetics*; D008297:Male; D008874:Midazolam / Q000031:analogs & derivatives / Q000097:blood / Q000493:pharmacokinetics; D055815:Young Adult
chemical_list: C001380:6 beta-hydroxycortisol; C040081:1-hydroxymethylmidazolam; D051544:Cytochrome P-450 CYP3A; D017291:Clarithromycin; D008874:Midazolam; D006854:Hydrocortisone
references.citation: Int J Clin Pharmacol Ther. 2000 Jan;38(1):1-9
references.pmid: 10667830
references.citation: J Steroid Biochem Mol Biol. 1992 Dec;43(7):713-9
references.pmid: 1472463
references.citation: Med Sci Monit. 2000 Mar-Apr;6(2):319-24
references.pmid: 11208330
references.citation: Methods Find Exp Clin Pharmacol. 2005 Oct;27(8):559-67
references.pmid: 16273136
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Nov 5;826(1-2):238-43
references.pmid: 16183337
references.citation: J Biol Chem. 1992 Dec 5;267(34):24248-52
references.pmid: 1360010
references.citation: Br J Clin Pharmacol. 2006 Aug;62(2):187-95
references.pmid: 16842393
references.citation: Eur J Clin Pharmacol. 2003 Dec;59(10):713-33
references.pmid: 14605790
references.citation: Steroids. 2003 May;68(5):477-82
references.pmid: 12798499
references.citation: Pharm Res. 2003 May;20(5):757-64
references.pmid: 12751631
references.citation: Clin Pharmacol Ther. 1992 Jan;51(1):18-23
references.pmid: 1732074
references.citation: Adv Drug Deliv Rev. 2008 Mar 17;60(6):717-33
references.pmid: 18199522
references.citation: Drug Metab Dispos. 2003 Nov;31(11):1283-7
references.pmid: 14570755
references.citation: Acta Pharmacol Sin. 2001 Jul;22(7):634-8
references.pmid: 11749829
references.citation: Clin Pharmacol Ther. 1993 Dec;54(6):621-9
references.pmid: 8275617
references.citation: Drug Metab Dispos. 2002 Aug;30(8):883-91
references.pmid: 12124305
references.citation: J Chromatogr B Biomed Sci Appl. 1998 Jun 12;710(1-2):165-71
references.pmid: 9686884
references.citation: Clin Pharmacokinet. 2002;41(7):453-70
references.pmid: 12083975
references.citation: Pharmacogenetics. 2000 Apr;10(3):187-216
references.pmid: 10803676
references.citation: Acta Med Hung. 1986;43(3):283-9
references.pmid: 3588168